source
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears marketNot a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reporte…BioSpace · 17d ago↗ source
- Trump pledges $90 one-time Medicare Part B premium payment to over 20 million seniors before midtermsPresident Donald Trump announced on social media that more than 20 million Medicare Part B enrollees will receive a one-time $90 payment to help cover their premiums. The promise comes days before…
- BMO sees Merck better positioned than BMS to handle looming patent cliffs